Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Vitamins Add-on in First-Episode Schizophrenia
NCT00140166Phase 4Completed
- Sponsor
- Be'er Sheva Mental Health Center
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nicotinamide, ascorbic acid and pyridoxine in schizophrenia (2 arms), sponsored by Be'er Sheva Mental Health Center. Primary endpoint: Brief Psychiatric Rating Scale at 6 months. Started Jul 2005; status: completed.
02
Drugs
nicotinamideascorbic acidpyridoxine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00140166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00140166.